News headlines about SAGE Therapeutics (NASDAQ:SAGE) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. SAGE Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.8890465962144 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news stories that may have effected Accern’s rankings:
- Investor’s Roundup (SMA’s Analysis) – Sage Therapeutics, Inc. (NASDAQ: SAGE) – The Investor Guide (wallstreetnews24.com)
- SAGE Therapeutics (SAGE) Earns “Buy” Rating from Cowen (americanbankingnews.com)
- Corbus Pharmaceuticals (CRBP) vs. SAGE Therapeutics (SAGE) Head-To-Head Contrast (americanbankingnews.com)
- Pre-Market Technical Scan on Biotech Equities — Riot Blockchain, Sage Therapeutics, Sarepta Therapeutics, and Sierra Oncology (bizjournals.com)
- Pre-Market Technical Scan on Biotech Equities — Riot Blockchain, Sage … (prnewswire.com)
A number of analysts have weighed in on the stock. BidaskClub raised shares of SAGE Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. Stifel Nicolaus reissued a “buy” rating and set a $198.00 target price on shares of SAGE Therapeutics in a report on Friday, December 8th. SunTrust Banks increased their target price on shares of SAGE Therapeutics to $203.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Morgan Stanley assumed coverage on shares of SAGE Therapeutics in a report on Monday, February 26th. They set an “overweight” rating and a $225.00 target price on the stock. Finally, Royal Bank of Canada dropped their target price on shares of SAGE Therapeutics from $145.00 to $137.00 and set an “outperform” rating on the stock in a report on Monday, November 27th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the company. SAGE Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $183.93.
SAGE Therapeutics (NASDAQ:SAGE) last released its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.75) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.98) by $0.23. During the same quarter last year, the firm posted ($1.50) EPS. sell-side analysts predict that SAGE Therapeutics will post -8.34 earnings per share for the current year.
In other SAGE Therapeutics news, insider Stephen Kanes sold 44,000 shares of the firm’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $177.18, for a total transaction of $7,795,920.00. Following the transaction, the insider now owns 46,348 shares of the company’s stock, valued at approximately $8,211,938.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Jeffrey M. Jonas sold 210,247 shares of the firm’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $157.45, for a total transaction of $33,103,390.15. Following the transaction, the chief executive officer now directly owns 211,473 shares in the company, valued at approximately $33,296,423.85. The disclosure for this sale can be found here. In the last three months, insiders have sold 312,386 shares of company stock worth $50,899,218. 6.10% of the stock is owned by corporate insiders.
About SAGE Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.